TRPV1 antagonists: the challenges for therapeutic targeting

Trends in Molecular Medicine

Volumn 15, Issue 1, 2009, Pages 14-22

  Khairatkar Joshi, Neelima ^a   Szallasi, Arpad ^b,c  

^a Glenmark Pharmaceuticals Limited   (India)

^b MONMOUTH MEDICAL CENTER   (United States)

^c DREXEL UNIVERSITY COLLEGE OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

1 (2 BROMOPHENYL) 3 [1 (5 TRIFLUOROMETHYL 2 PYRIDINYL) 3 PYRROLIDINYL]UREA; A 425619; AMG 517; AMG 9810; AZD 1386; GRC 6211; JTS 653; NGD 8243; PF 4383119; PROTEIN TRPV 1 ANTAGONIST; SB 705498PF 4383119; UNCLASSIFIED DRUG; VANILLOID RECEPTOR 1;

ARTICLE; ASTHMA; BLADDER DYSFUNCTION; BRAIN CELL; CHRONIC OBSTRUCTIVE LUNG DISEASE; CHRONIC PAIN; CLINICAL TRIAL; COUGHING; DENDRITIC CELL; DNA POLYMORPHISM; ENDOTHELIUM CELL; HUMAN; HYPERTHERMIA; INFLAMMATION; INTERSTITIAL CYSTITIS; KERATINOCYTE; LOW BACK PAIN; LYMPHOCYTE; MAST CELL; MIGRAINE; NEUROIMMUNOLOGY; NEUROPATHIC PAIN; NOCICEPTION; NONHUMAN; OSTEOARTHRITIS; OVERACTIVE BLADDER; SENSORY NERVE CELL; SMOOTH MUSCLE FIBER; TOOTH PAIN;

DRUG DELIVERY SYSTEMS; HUMANS; INFLAMMATION; PAIN; POLYMORPHISM, GENETIC; SIGNAL TRANSDUCTION; TRPV CATION CHANNELS;

EID: 58149483491     PISSN: 14714914     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.molmed.2008.11.004     Document Type: Article

References (92)

1. Szallasi A., et al. The vanilloid receptor TRPV1: 10 years from channel cloning to antagonist proof-of-concept. Nat. Rev. Drug Discov. 6 (2007) 357-372
2. Caterina M.J., et al. The capsaicin receptor: a heat activated ion channel in pain pathway. Nature 389 (1997) 816-824
3. Tominaga M., et al. The cloned capsaicin receptor integrates multiple pain-producing stimuli. Neuron 21 (1998) 531-543
4. Caterina M.J., et al. Impaired nociception and pain sensation in mice lacking the capsaicin receptor. Science 288 (2000) 306-313
5. Davis J.B., et al. Vanilloid receptor-1 is essential for inflammatory thermal hyperalgesia. Nature 405 (2000) 183-187
6. Kasama S., et al. RNA interference-mediated knock-down of transient receptor potential vanilloid 1 prevents forepaw inflammatory hyperalgesia in rat. Eur. J. Neurosci. 25 (2007) 2956-2963
7. Kamei J., et al. Role of vanilloid receptors in thermal allodynia and hyperalgesia in diabetic mice. Eur. J. Pharmacol. 422 (2001) 83-86
8. Rami H.K., and Gunthorpe M.J. The therapeutic potential of TRPV1 (VR1) antagonists: clinical answers await. Drug Discov. Today 1 (2004) 97-104
9. Gunthorpe M.J., and Szallasi A. Peripheral TRPV1 receptors as targets for drug development: new molecules and mechanisms. Curr. Pharm. Des. 14 (2008) 32-41
10. Feltynek, C. and Gomtsyan, A., eds Vanilloid receptor TRPV1 in Drug Discovery: Targeting Pain and other Pathological Disorders, John Wiley & Sons (in press)
11. In: Malmberg A., and Bley K.R. (Eds). Turning up the Heat on Pain: TRPV1 Receptors in Pain and Inflammation (2005), Birkhauser
12. Szallasi A., and Di Marzo V. New perspectives on enigmatic vanilloid receptors. Trends Neurosci. 23 (2000) 491-497
13. Morgese M.G., et al. Anti-dyskinetic effects of cannabinoids in a rat model of Parkinson's disease: role of CB1 and TRPV1 receptors. Exp. Neurol. 208 (2007) 110-119
14. Chahl L.A. TRPs: links to schizophrenia? Biochim. Biophys. Acta 1772 (2008) 968-977
15. Yamamoto S., et al. Transient release potential channels in Alzheimer's disease. Biochim. Biophys. Acta 1772 (2008) 958-967
16. Gibson H.E., et al. TRPV1 channels mediate long term depression atsynapses on hippocampal interneurons. Neuron 57 (2008) 746-759
17. Di Marzo V., et al. Brain TRPV1: a depressing TR(i)P down memory lane?. Trends Pharmacol. Sci. 12 (2008) 594-600
18. Cui M., et al. TRPV1 receptors in the CNS play a key role in broad spectrum analgesia of TRPV1 antagonists. J. Neurosci. 26 (2006) 9385-9393
19. Stander S., et al. Expression of vanilloid receptor subtype-1 in cutaneous sensory fibers, mast cells and epithelial cells of appendage structure. Exp. Dermatol. 13 (2004) 129-139
20. Kim J., et al. Identification of functional vanilloid receptors in human bladder urothelial cells using a nitric oxide micro sensor technique and reverse transcriptase polymerase chain reaction. J. Urol. 165 (2001) 34
21. Kark T., et al. Tissue-specific regulation of microvascular diameter: opposite functional roles of neuronal and smooth muscle located vanilloid receptor-1. Mol. Pharmacol. 73 (2008) 1405-1412
22. Golech S.A., et al. Human brain endothelium: co expression and function of vanilloid and endocannabinoid receptors. Brain Res. Mol. Brain Res. 132 (2004) 87-92
23. Cortright, D.N. and Szallasi, A. The role of TRPV1 and related receptors in nociceptor function and neuroimmune regulation. In Neuroimmune Biology, Vol. 8. Neurogenic Inflammation and Health and Disease (Bérczy, I., ed.), Elsevier (in press)
24. Southall M.D., et al. Activation of epidermal vanilloid receptor-1 induces release of proinflammatory mediators in human keratinocytes. J. Pharmacol. Exp. Ther. 304 (2003) 217-222
25. Paus R., et al. Substance P stimulates murine epidermal keratinocyte proliferation and dermal mast cell degranulation. Arch. Dermatol. Res. 287 (1995) 500-502
26. Staniek V., et al. Expression of substance P receptors in normal and psoriatic skin. Pathobiology 67 (1999) 51-54
27. Arnold W.P., and van der Kerkhof P.C. Topical capsaicin for pruritic psoriasis. J. Am. Acad. Dermatol. 31 (1994) 135
28. + sensory neurons control beta cell stress and islet inflammation in autoimmune diabetes. Cell 127 (2006) 1123-1135
29. Di Marzo V., et al. Endovanilloid signaling in pain. Curr. Opin. Neurobiol. 12 (2002) 372-380
30. Zygmunt P.M., et al. Vanilloid receptors on sensory nerves mediate the vasodilator action of anandamide. Nature 400 (1999) 452-457
31. In: Geppetti P., and Holzer P. (Eds). Neurogenic Inflammation (1996), CRC Press
32. Kamei J., et al. Effect of N-arachidonoyl-(2-methyl-4-hydroxyphenyl) amine (VDM11), an anandamide transporter inhibitor, on capsaicin-induced cough in mice. Cough 2 (2006) 2-10
33. Jia Y., et al. Anandamide induces cough in conscious guinea-pigs through VR1 receptors. Br. J. Pharmacol. 137 (2002) 831-836
34. Lalloo U.G., et al. Capsazepine inhibits cough induced by capsaicin and citric acid but not hypertonic saline in guinea pigs. J. Appl. Physiol. 79 (1995) 1082-1087
35. Bhattacharya A., et al. Pharmacology and antitussive efficacy of 4-(3-trifluoromethyl-2-yl)-piperazine-1-carboxylic acid (5-trifluromethyl-pyridin-2-yl)-amide (JNJ17203212), a TRPV1 antagonist in guinea pigs. J. Pharmacol. Exp. Ther. 323 (2007) 665-674
36. Bonini S., et al. Circulating nerve growth factor levels are increased in humans with allergic diseases and asthma. Proc. Natl. Acad. Sci. U. S. A. 93 (1996) 10955-10960
37. Virchow J.C., et al. Neurotrophins are increases in broncho-alveolar lavage fluid after segmental allergen provocation. Am. J. Respir. Crit. Care Med. 158 (1998) 2002-2005
38. Holtzman M.J. Arachidonic acid metabolism in airway epithelial cells. Annu. Rev. Physiol. 54 (1992) 303-329
39. Reeh P.W., and Steen K.H. Tissue acidosis in nociception and pain. Prog. Brain Res. 113 (1996) 143-151
40. Agopyan N., et al. Negatively charged 2- and 10-micron particles activate vanilloid receptors, increase cAMP, and induce cytokine release. Toxicol. Appl. Pharmacol. 186 (2003) 63-76
41. Nilsson G., et al. Local immune response and bronchial reactivity in rats after capsaicin treatment. Allergy 46 (1991) 304-311
42. De Groat W.C. The urothelium: passive bystander or active participant?. Urology 64 (2004) 7-11
43. Birder L.A. Urinary bladder urothelium: molecular sensors of chemical/thermal/mechanical stimuli. Vascul. Pharmacol. 45 (2006) 221-226
44. Silva C., et al. TRPV1 knock out mice do not develop bladder over activity during acute chemical bladder inflammation. Soc. Neurosci. Abst. 288 (2004) 16
45. Szallasi A., et al. TRPV1: a therapeutic target for novel analgesic drugs?. Trends Mol. Med. 12 (2006) 545-554
46. Lazzeri M., et al. Intravesical vanilloid therapy and neurogenic incontinence: ten years experience. Urol. Int. 72 (2004) 145-149
47. Charrua, A. et al. GRC 6211 sulphate a new specific oral TRPV1 antagonist reduces bladder overactivity and noxious bladder input in cystitis animal models. J. Urol. (in press)
48. Andrews P.L., and Bhandari P. Resiniferatoxin, an ultrapotent capsaicin analogue, has antiemetic properties in the ferret. Neuropharmacology 32 (1993) 799-806
49. Gavva N. Body-temperature maintenance as a predominant function of the vanilloid receptor TRPV1. Trends Pharmacol. Sci. 11 (2008) 550-557
50. Kim, H. and Dionne, R.A. TRP polymorphism: implications for theranostics. In TRP Channels in Health and Disease: Implications for Diagnosis and Therapy (Szallasi, A., ed.), Nova Publishing (in press)
51. Pingle S.C., et al. Capsaicin receptor TRPV1: a promiscuous TRP channel. Handb. Exp. Pharmacol. 179 (2007) 155-171
52. Jordt S.E., et al. Acid potentiation of the capsaicin receptor determined by a key extracellular site. Proc. Natl. Acad. Sci. U. S. A. 97 (2000) 8134-8139
53. Chuang H.H., et al. Bradykinin and nerve growth factor release the capsaicin receptor from PtdIns(4,5)P2-mediated inhibition. Nature 411 (2001) 957-962
54. Zhang X., et al. Proinflammatory mediators modulate the heat-activated ion channel TRPV1 via the scaffolding protein AKAP79/150. Neuron 59 (2008) 450-461
55. Gavva N.R., et al. Molecular determinants of vanilloid sensitivity in TRPV1. J. Biol. Chem. 279 (2004) 20283-20295
56. Tousova K., et al. Gadolinium activates and sensitizes the vanilloid receptor TRPV1 through the external protonation sites. Mol. Cell. Neurosci. 30 (2005) 207-217
57. Brauchi S., et al. A hot sensing cold receptor: C-terminal domain determines thermosensation in transient receptor potential channels. J. Neurosci. 26 (2006) 4835-4840
58. Gavva N.R., et al. Proton activation does not alter antagonist interaction with the capsaicin binding pocket of TRPV1. Mol. Pharm. 68 (2005) 1524-1533
59. Klionsky L., et al. A polyclonal antibody to the prepore loop of transient receptor potential vanilloid type 1 blocks channel activation. J. Pharmacol. Exp. Ther. 319 (2006) 192-198
60. Ohta T., et al. Novel gating and sensitizing mechanism of capsaicin receptor (TRPV1): tonic inhibitory regulation of extracellular sodium through the extra cellular protonation site on TRPV1. J. Biol. Chem. 283 (2008) 9377-9387
61. Sculptoreanu A., et al. Protein kinase C contributes to abnormal capsaicin responses in DRG neurons from cats with feline interstitial cystitis. Neurosci. Lett. 381 (2005) 42-46
62. Chung M.K., et al. TRPV1 shows dynamic ionic selectivity during agonist stimulation. Nat. Neurosci. 11 (2008) 555-564
63. Kedei N., et al. Analysis of the native quaternary structure of the vanilloid receptor-1. J. Biol. Chem. 276 (2001) 28613-28619
64. Mandadi S., et al. Increased sensitivity of desensitized TRPV1 by PMA occurs through PKCε-mediated phosphorylation at S800. Pain 123 (2006) 106-116
65. García-Sanz N., et al. Identification of a tetramerization domain in the C terminus of the vanilloid receptor 1. J. Neurosci. 24 (2004) 5307-5314
66. Garcia-Sanz N., et al. A role of the transient receptor potential domain of vanilloid receptor I in channel gating. J. Neurosci. 27 (2007) 11641-11650
67. Diatchenko L., et al. Genetic basis for individual variations in pain perception and development of a chronic pain condition. Hum. Mol. Genet. 14 (2005) 135-143
68. Serý O., et al. Pain research update from a genetic point of view. Pain Pract. 5 (2005) 341-348
69. Bruehl S., et al. The mu opioid receptor A118G gene polymorphism moderates effects of trait anger-out on acute pain sensitivity. Pain 139 (2008) 406-415
70. Lötsch J., and Geisslinger G. Are μ opioid receptor polymorphisms important for clinical opioid therapy? Trends Mol. Med. 11 (2005) 82-89
71. Diatchenko L., et al. Catechol-o-methyltransferase gene polymorphisms are associated with multiple pain-evoking stimuli. Pain 125 (2006) 216-224
72. Kim H., et al. Genetic predictors for acute experimental cold and heat pain sensitivity to humans. J. Med. Genet. 43 (2006) e40
73. Goldberg Y.P., et al. Loss-of-function mutations in the Nav1.7 gene underlie congenital indifference to pain in multiple human populations. Clin. Genet. 71 (2007) 311-319
74. Oertel B., and Lötsch J. Genetic mutations that prevent pain: implications for future pain medication. Pharmacogenomics 9 (2008) 179-194
75. Hongshi X., et al. Functional effects of non-synchronous polymorphism in the human TRPV1 gene. Am. J. Physiol. Renal Physiol. 293 (2007) F1865-F1876
76. Paule, C. et al. (2007) Human TRPV1 polymorphs show different sensitivity to various activators [abstract L115]. In Neuropeptides 2007 - Function, Dysfunction and Therapeutic Options - Santorini, Greece, 19-21 April, 2007, Neuropeptides 42, 471
77. Kim H., et al. Genetic influence on variability in human acute and experimental pain sensitivity associated with gender, ethnicity and psychological temperament. Pain 109 (2004) 488-496
78. Garcia-Bailo B., et al. Genetic variation in taste and its influence on food selection. OMICS (2008). http://www.liebertonline.com/loi/omi 10.1089/omi.2008.0031
79. Motter A.L., and Ahern G.P. TRPV1-null mice are protected from diet-induced obesity. FEBS Lett. 582 (2008) 2257-2262
80. Westerterp-Plantenga M.S., et al. Sensory and gastrointestinal satiety effects of capsaicin on food intake. Int. J. Obes. 29 (2005) 682-688
81. Christoph T., et al. Silencing of vanilloid receptor TRPV1 by RNAi reduces neuropathic and visceral pain in vivo. Biochem. Biophys. Res. Commun. 350 (2006) 238-243
82. Thomas C., et al. Antinociceptive effect of antisense oligonucleotides against the vanilloid receptor VR1/TRPV1. Neurochem. Int. 170 (2006) 457-462
83. Knotkova H., et al. Capsaicin (TRPV1 agonist) therapy for pain relief: farewell or revival? Clin. J. Pain 24 (2008) 142-154
84. Cortright, D.D. and Szallasi, A. TRP channels and pain. Curr. Pharm. Des. (in press)
85. Gharat L., and Szallasi A. Advances in the design and therapeutic use of capsaicin receptor TRPV1 agonists and antagonists. Exp. Opin. Ther. Pa*tents 18 (2008) 159-209
86. Levine J.D., and Alessandri-Haber N. TRP channels: targets for the relief of pain. Biochim. Biophys. Acta 1772 (2007) 989-1003
87. Gavva N.R., et al. Repeated administration of vanilloid receptor TRPV1 antagonists attenuates hyperthermia elicited by TRPV1 blockade. J. Pharmacol. Exp. Ther. 323 (2007) 128-137
88. Gavva N.R., et al. Pharmacological blockade of the vanilloid receptor TRPV1 elicits marked hyperthermia in humans. Pain 136 (2008) 202-210
89. Lehto S.G., et al. Antihyperalgesic effects of (R,E)-N-(2-Hydroxy-2,3-dihydro-1H-inden-4-yl)-3-(2-(piperidin-1-yl)-4-(trifluoromethyl)phenyl)-acrylamide (AMG8562), a novel transient receptor potential vanilloid type modulator that does not cause hyperthermia in rats. J. Pharmacol. Exp. Ther. 326 (2008) 218-229
90. Trevisani, M. et al. (2008) V377, a potent TRPV1 antagonist for pain management [abstract]. In European Opioid Conference, European Neuropeptide Club: 2008 April 8-11; Ferrara, p.25 (http://www.eocweb.com/pdf_docs/EOC-ENC_Abstract_book.pdf)
91. Mills C., et al. Effects of the transient receptor potential vanilloid 1 antagonist A-425619 on body temperature and thermoregulation in the rat. Neurosci. 156 (2008) 165-174
92. Chizh B.A., et al. The effects of the TRPV1 receptor antagonist SB-705498 on TRPV1 receptor-mediated activity and inflammatory hyperalgesia in humans. Pain 132 (2007) 132-141